Should I buy or sell Adicet Bio stock right now?

7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares. View ACET analyst ratings or view top-rated stocks .

What is Adicet Bio's stock price target for 2024?

7 brokers have issued twelve-month price objectives for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,023.2% from the stock's current price. View analysts price targets for ACET or view top-rated stocks among Wall Street analysts .

How have ACET shares performed in 2023?

Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 84.6% and is now trading at $1.38. View the best growth stocks for 2023 here .

Are investors shorting Adicet Bio?

Adicet Bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Based on an average daily volume of 392,400 shares, the short-interest ratio is currently 7.7 days. Currently, 10.0% of the shares of the company are short sold. View Adicet Bio's Short Interest .

When is Adicet Bio's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our ACET earnings forecast .

How were Adicet Bio's earnings last quarter?

Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02.

Is Adicet Bio a good dividend stock?

Adicet Bio (NASDAQ:ACET) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.00%. Read our dividend analysis for ACET .

What other stocks do shareholders of Adicet Bio own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI) , Aurora Cannabis (ACB) , Twitter (TWTR) , QUALCOMM (QCOM) , Extreme Networks (EXTR) , General Electric (GE) , Altria Group (MO) , Sirius XM (SIRI) and Adobe (ADBE) .

Who are Adicet Bio's major shareholders?

Adicet Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (6.30%), Acadian Asset Management LLC (1.21%), Jacobs Levy Equity Management Inc. (0.77%), Northern Trust Corp (0.53%), Decheng Capital Management III Cayman LLC (0.46%) and GSA Capital Partners LLP (0.33%). Insiders that own company stock include Andrew Sinclair , Aya Jakobovits , Blake Aftab, Carl L Gordon, Chen Schor , Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin. View institutional ownership trends .

How do I buy shares of Adicet Bio?

Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull , Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here .

Adicet Bio Stock Price, News & Analysis (NASDAQ:ACET)

$1.38

+0.01 (+0.73%)

(As of 12/8/2023 ET)

Compare

Today's Range: $1.27
▼
$1.41
50-Day Range: $1.11
▼
$1.65
52-Week Range: $1.10
▼
$19.84

Volume: 302,863 shs
Average Volume: 570,167 shs
Market Capitalization: $59.57 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $15.50

Adicet Bio MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.57 Rating Score
Upside/Downside: 1,023.2% Upside
$15.50 Price Target
Short Interest: Bearish
9.98% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Acquiring Shares
$15,125 Bought Last Quarter
Proj. Earnings Growth: Growing
From ($2.90) to ($2.11) Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.10 out of 5 stars

Medical Sector

427th out of 954 stocks

Pharmaceutical Preparations Industry

140th out of 362 stocks

3.3

Analyst's Opinion

Consensus Rating
Adicet Bio has received a consensus rating of Moderate Buy. The company's average rating score is 2.57, and is based on 4 buy ratings, 3 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $15.50, Adicet Bio has a forecasted upside of 1,023.2% from its current price of $1.38.
Amount of Analyst Coverage
Adicet Bio has only been the subject of 1 research reports in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
9.98% of the float of Adicet Bio has been sold short.
Short Interest Ratio / Days to Cover
Adicet Bio has a short interest ratio ("days to cover") of 7.7.
Change versus previous month
Short interest in Adicet Bio has recently increased by 6.69%, indicating that investor sentiment is decreasing significantly.

0.0

Dividend Strength

Dividend Yield
Adicet Bio does not currently pay a dividend.
Dividend Growth
Adicet Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for ACET.

0.6

News and Social Media Coverage

News Coverage This Week
MarketBeat has tracked 1 news article for Adicet Bio this week, compared to 1 article on an average week.
Search Interest
Only 5 people have searched for ACET on MarketBeat in the last 30 days. This is a decrease of -72% compared to the previous 30 days.
MarketBeat Follows
2 people have added Adicet Bio to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.

5.0

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Adicet Bio insiders have bought more of their company's stock than they have sold. Specifically, they have bought $15,125.00 in company stock and sold $0.00 in company stock.
Percentage Held by Insiders
29.50% of the stock of Adicet Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
85.29% of the stock of Adicet Bio is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Adicet Bio are expected to grow in the coming year, from ($2.90) to ($2.11) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Adicet Bio is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Adicet Bio is -0.41, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Adicet Bio has a P/B Ratio of 0.20. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Adicet Bio Stock (NASDAQ:ACET)

Adicet Bio, Inc., a clinical stage biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and chimeric adaptors to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and enhance persistence for durable activity in patients. Its lead product in pipeline includes ADI-001, which is in Phase I clinical study for the treatment of non-Hodgkin's lymphoma. The company also develops ADI-002, which is undergoing preclinical studies for the treatment of various solid tumors; and ADI-925, a novel engineered CAd gamma delta T cell product candidate targeting tumor stress ligands. Adicet Bio, Inc. is based in Boston, Massachusetts.

ACET Stock Price History

30 days | 90 days | 365 days | Advanced Chart

ACET Stock News Headlines

December 7, 2023 | morningstar.com

Adicet Bio Inc Ordinary Shares

November 16, 2023 | markets.businessinsider.com

Analysts Have Conflicting Sentiments on These Healthcare Companies: Terns Pharmaceuticals (TERN) and Adicet Bio (ACET)

December 8, 2023 | Autonomix (Ad)

How to Invest Early In the Next Potential Breakthrough Nerve-Sensing Technology

Autonomix is preparing a public listing as they develop technology to potentially detect and treat a range of nervous system disorders with much greater visibility than available today. Now, their management team sees a potentially untapped $100B market opportunity.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 10, 2023 | markets.businessinsider.com

Adicet Bio: Buy Rating Driven by Strategic Overhaul and Promising Oncology Developments

November 9, 2023 | markets.businessinsider.com

Wedbush Maintains Outperform Rating for Adicet Bio: Here's What You Need To Know

November 8, 2023 | seekingalpha.com

Adicet Bio GAAP EPS of -$1.16

November 8, 2023 | markets.businessinsider.com

Adicet Bio, Inc Q3 Loss increases, misses estimates

November 7, 2023 | finance.yahoo.com

Adicet Bio to Present at the 2023 Jefferies London Healthcare Conference

December 8, 2023 | Autonomix (Ad)

[Investor Alert] Potential Breakthrough Medical Tech Investment Opportunity

Autonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.com

November 2, 2023 | finance.yahoo.com

Adicet Bio Announces Poster Presentation Highlighting ADI-001 Data at the 65th American Society of Hematology (ASH) Annual Meeting

October 31, 2023 | finance.yahoo.com

Adicet Bio Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

October 4, 2023 | finance.yahoo.com

Adicet Bio Announces Poster Presentation at the Upcoming 2023 Molecular Targets and Cancer Therapeutics Conference

September 27, 2023 | finance.yahoo.com

Adicet Bio to Present Three Scientific Posters Highlighting its Allogeneic Gamma Delta T Cell Platform and Programs at the Society for Immunotherapy of Cancer (SITC) 38th Annual Meeting

September 6, 2023 | msn.com

Truist Securities Reiterates Adicet Bio (ACET) Buy Recommendation

August 12, 2023 | finance.yahoo.com

Will Adicet Bio (NASDAQ:ACET) Spend Its Cash Wisely?

August 11, 2023 | msn.com

BTIG Maintains Adicet Bio (ACET) Buy Recommendation

August 9, 2023 | finance.yahoo.com

Adicet Bio, Inc. (ACET) Reports Q2 Loss, Lags Revenue Estimates

August 9, 2023 | markets.businessinsider.com

Adicet Bio, Inc Q2 Loss increases, misses estimates

August 9, 2023 | finance.yahoo.com

Adicet Reports Second Quarter 2023 Financial Results and Provides Business Updates

August 3, 2023 | finance.yahoo.com

Adicet Bio to Participate in a Fireside Chat at the Canaccord Genuity 43rd Annual Growth Conference

July 12, 2023 | benzinga.com

Adicet Bio Director Awarded $236K Worth of Stock Options

July 11, 2023 | finance.yahoo.com

Adicet Announces Appointment of Katie Peng to the Board of Directors

July 6, 2023 | msn.com

Adicet Bio (ACET) Price Target Decreased by 12.90% to 24.48

June 30, 2023 | benzinga.com

Massive Insider Trade At Adicet Bio

June 30, 2023 | benzinga.com

Director of Adicet Bio Purchased $1.83M In Stock

June 27, 2023 | msn.com

JMP downgrades Adicet to market perform, citing study delay

June 27, 2023 | msn.com

Adicet Bio Stock Craters 54% after JMP Downgrade

See More Headlines

Receive ACET Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Adicet Bio and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 11/08/2023
Today: 12/08/2023
Fiscal Year End: 12/31/2023
Next Earnings (Estimated): 3/20/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: Trading Companies & Distributors
Sector: Medical
Current Symbol: NASDAQ:ACET
CUSIP: 00444610
CIK: 2034
Web: www.aceto.com
Phone: (650) 503-9095
Fax: N/A
Employees: 132
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $15.50
High Stock Price Target: $27.00
Low Stock Price Target: $5.00
Potential Upside/Downside: +1,023.2%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.57
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.35)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-69,790,000.00
Net Margins: N/A
Pretax Margin: N/A
Return on Equity: -49.82%
Return on Assets: -43.11%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 9.40
Quick Ratio: 9.40

Sales & Book Value

Annual Sales: $24.99 million
Price / Sales: 2.38
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $6.82 per share
Price / Book: 0.20

Miscellaneous

Outstanding Shares: 43,165,000
Free Float: 30,431,000
Market Cap: $59.57 million
Optionable: Optionable
Beta: 1.86

12 Stocks Corporate Insiders are Abandoning

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

Mr. Chen Schor BA (Age 51)
CPA, M.B.A., CEO, President & Director
Comp: $899.58k
Dr. Aya Jakobovits Ph.D. (Age 68)
Founder & Independent Director
Comp: $40k
Dr. Blake Aftab Ph.D. (Age 42)
Senior VP & Chief Scientific Officer
Comp: $675.04k
Dr. Francesco Galimi M.D. (Age 55)
Ph.D., Chief Medical Officer & Senior VP
Comp: $680.37k
Mr. Brian Nicholas Harvey (Age 62)
Chief Financial Officer
Comp: $596.79k
Dr. Donald Healey Ph.D. (Age 61)
Chief Technology Officer
Ms. Amy Locke
Head of Human Resources
Dr. Nancy L. Boman M.D.
Ph.D., Senior VP & Chief Regulatory Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

ACET Stock Analysis - Frequently Asked Questions

Should I buy or sell Adicet Bio stock right now?: 7 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Adicet Bio in the last twelve months. There are currently 3 hold ratings and 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "moderate buy" ACET shares.
View ACET analyst ratings or view top-rated stocks.
What is Adicet Bio's stock price target for 2024?: 7 brokers have issued twelve-month price objectives for Adicet Bio's shares. Their ACET share price targets range from $5.00 to $27.00. On average, they predict the company's stock price to reach $15.50 in the next twelve months. This suggests a possible upside of 1,023.2% from the stock's current price.
View analysts price targets for ACET or view top-rated stocks among Wall Street analysts.
How have ACET shares performed in 2023?: Adicet Bio's stock was trading at $8.94 at the beginning of 2023. Since then, ACET shares have decreased by 84.6% and is now trading at $1.38.
View the best growth stocks for 2023 here.
Are investors shorting Adicet Bio?: Adicet Bio saw a increase in short interest during the month of November. As of November 15th, there was short interest totaling 3,030,000 shares, an increase of 6.7% from the October 31st total of 2,840,000 shares. Based on an average daily volume of 392,400 shares, the short-interest ratio is currently 7.7 days. Currently, 10.0% of the shares of the company are short sold.
View Adicet Bio's Short Interest.
When is Adicet Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024.
View our ACET earnings forecast.
How were Adicet Bio's earnings last quarter?: Adicet Bio, Inc. (NASDAQ:ACET) announced its earnings results on Wednesday, November, 8th. The company reported ($0.71) EPS for the quarter, topping the consensus estimate of ($0.73) by $0.02.

Is Adicet Bio a good dividend stock?: Adicet Bio (NASDAQ:ACET) pays an annual dividend of $0.04 per share and currently has a dividend yield of 0.00%.
Read our dividend analysis for ACET.
What other stocks do shareholders of Adicet Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Adicet Bio investors own include FluoroPharma Medical (FPMI), Aurora Cannabis (ACB), Twitter (TWTR), QUALCOMM (QCOM), Extreme Networks (EXTR), General Electric (GE), Altria Group (MO), Sirius XM (SIRI) and Adobe (ADBE).
Who are Adicet Bio's major shareholders?: Adicet Bio's stock is owned by many different institutional and retail investors. Top institutional shareholders include Cowen AND Company LLC (6.30%), Acadian Asset Management LLC (1.21%), Jacobs Levy Equity Management Inc. (0.77%), Northern Trust Corp (0.53%), Decheng Capital Management III Cayman LLC (0.46%) and GSA Capital Partners LLP (0.33%). Insiders that own company stock include Andrew Sinclair, Aya Jakobovits, Blake Aftab, Carl L Gordon, Chen Schor, Don Healey, Francesco Galimi, Jay P Elliott and Steve Dubin.
View institutional ownership trends.
How do I buy shares of Adicet Bio?: Shares of ACET stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

This page (NASDAQ:ACET) was last updated on 12/8/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial